| Name | N-[2-[(2,3-difluorophenyl)methylsulfanyl]-6-[[(2R,3R)-3,4-dihydroxybutan-2-yl]amino]pyrimidin-4-yl]azetidine-1-sulfonamide |
|---|---|
| Synonyms |
Y0301
CS-0977 1-Azetidinesulfonamide, N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[[(1R,2R)-2,3-dihydroxy-1-methylpropyl]amino]-4-pyrimidinyl]- SRT-3109 cc-200 N-(2-[(2,3-Difluorobenzyl)sulfanyl]-6-{[(2R,3R)-3,4-dihydroxy-2-butanyl]amino}-4-pyrimidinyl)-1-azetidinesulfonamide SRT3109 |
| Description | SRT3109 is an antagonist of CXCR2, with a pIC50 of 8.2, and used in the research of chemokine mediated diseases. |
|---|---|
| Related Catalog | |
| Target |
CXCR2:8.2 (pIC50) |
| In Vitro | SRT3109 (Example 1) is an antagonist of CXCR2, with a pIC50 of 8.2, and used in the research of chemokine mediated diseases[1]. |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 726.6±70.0 °C at 760 mmHg |
| Molecular Formula | C18H23F2N5O4S2 |
| Molecular Weight | 475.533 |
| Flash Point | 393.3±35.7 °C |
| Exact Mass | 475.115936 |
| PSA | 161.36000 |
| LogP | 2.07 |
| Vapour Pressure | 0.0±2.5 mmHg at 25°C |
| Index of Refraction | 1.661 |
| Storage condition | 2-8℃ |
|
~62%
1204707-71-0 |
| Literature: MEGHANI, PREMJI; ROBBINS, ANDREW JAMES; STONEHOUSE, JEFFREY PAUL Patent: US2010/16275 A1, 2010 ; Location in patent: Page/Page column 12 ; |
|
~64%
1204707-71-0 |
| Literature: MEGHANI, PREMJI; ROBBINS, ANDREW JAMES; STONEHOUSE, JEFFREY PAUL Patent: US2010/16275 A1, 2010 ; Location in patent: Page/Page column 14 ; |
| Precursor 3 | |
|---|---|
| DownStream 0 | |